A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Dial-in numbers:
Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United States 1 800 715 9871
Japan 81 3 4578 9081
Switzerland 41 43 210 11 32
Use the access code 1231519 to join the call. Please dial in 15 minutes prior to the live call.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the
For further information, please contact:
Media:
BPetok@argenx.com
Investors:
aroy@argenx.com
lelton@argenx.com